Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results

WHO Solidarity trial consortium, Hongchao Pan, Richard Peto, Quarraisha Abdool Karim, Marissa Alejandria, Ana Maria Henao-Restrepo, César Hernández García, Marie-Paule Kieny, Reza Malekzadeh, Srinivas Murthy, Marie-Pierre Preziosi, Srinath Reddy, Mirta Roses Periago, Vasee Sathiyamoorthy, John-Arne Røttingen, Soumya Swaminathan, as the members of the Writing Committee, assume responsibility for the content and integrity of this article
doi: https://doi.org/10.1101/2020.10.15.20209817
1Nuffield Department of Population Health, University of Oxford, Oxford
Hongchao Pan
1Nuffield Department of Population Health, University of Oxford, Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Peto
1Nuffield Department of Population Health, University of Oxford, Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Quarraisha Abdool Karim
2Centre for the AIDS Programme of Research In South Africa (CAPRISA), Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marissa Alejandria
3National Institutes of Health, Manila, University of the Philippines, Manila
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Maria Henao-Restrepo
11World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
César Hernández García
4Agency of Medicine and Medical Devices, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Paule Kieny
5Institut National de la Santé Et de la Recherche Médicale (INSERM), Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reza Malekzadeh
6Ministry of Health and Medical Education, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Srinivas Murthy
7University of British Columbia, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Pierre Preziosi
11World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Srinath Reddy
8Public Health Foundation of India, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mirta Roses Periago
9National Academy of Sciences of Buenos Aires, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vasee Sathiyamoorthy
11World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John-Arne Røttingen
10Research Council of Norway, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soumya Swaminathan
11World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

BACKGROUND WHO expert groups recommended mortality trials in hospitalized COVID-19 of four re-purposed antiviral drugs.

METHODS Study drugs were Remdesivir, Hydroxychloroquine, Lopinavir (fixed-dose combination with Ritonavir) and Interferon-β1a (mainly subcutaneous; initially with Lopinavir, later not). COVID-19 inpatients were randomized equally between whichever study drugs were locally available and open control (up to 5 options: 4 active and local standard-of-care). The intent-to-treat primary analyses are of in-hospital mortality in the 4 pairwise comparisons of each study drug vs its controls (concurrently allocated the same management without that drug, despite availability). Kaplan-Meier 28-day risks are unstratified; log-rank death rate ratios (RRs) are stratified for age and ventilation at entry.

RESULTS In 405 hospitals in 30 countries 11,266 adults were randomized, with 2750 allocated Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon plus Lopinavir, 1412 only Interferon, and 4088 no study drug. Compliance was 94-96% midway through treatment, with 2-6% crossover. 1253 deaths were reported (at median day 8, IQR 4-14). Kaplan-Meier 28-day mortality was 12% (39% if already ventilated at randomization, 10% otherwise). Death rate ratios (with 95% CIs and numbers dead/randomized, each drug vs its control) were: Remdesivir RR=0.95 (0.81-1.11, p=0.50; 301/2743 active vs 303/2708 control), Hydroxychloroquine RR=1.19 (0.89-1.59, p=0.23; 104/947 vs 84/906), Lopinavir RR=1.00 (0.79-1.25, p=0.97; 148/1399 vs 146/1372) and Interferon RR=1.16 (0.96-1.39, p=0.11; 243/2050 vs 216/2050). No study drug definitely reduced mortality (in unventilated patients or any other subgroup of entry characteristics), initiation of ventilation or hospitalisation duration.

CONCLUSIONS These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. The mortality findings contain most of the randomized evidence on Remdesivir and Interferon, and are consistent with meta-analyses of mortality in all major trials. (Funding: WHO. Registration: ISRCTN83971151, NCT04315948)

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ISRCTN83971151, NCT04315948

Funding Statement

Funding was from WHO. No external funding was received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Research Ethics Committees in each country and WHO Ethics Review Committee

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

These are interim results. Once the final database is locked, data sharing requests will be considered.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 15, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results
WHO Solidarity trial consortium, Hongchao Pan, Richard Peto, Quarraisha Abdool Karim, Marissa Alejandria, Ana Maria Henao-Restrepo, César Hernández García, Marie-Paule Kieny, Reza Malekzadeh, Srinivas Murthy, Marie-Pierre Preziosi, Srinath Reddy, Mirta Roses Periago, Vasee Sathiyamoorthy, John-Arne Røttingen, Soumya Swaminathan, as the members of the Writing Committee, assume responsibility for the content and integrity of this article
medRxiv 2020.10.15.20209817; doi: https://doi.org/10.1101/2020.10.15.20209817
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results
WHO Solidarity trial consortium, Hongchao Pan, Richard Peto, Quarraisha Abdool Karim, Marissa Alejandria, Ana Maria Henao-Restrepo, César Hernández García, Marie-Paule Kieny, Reza Malekzadeh, Srinivas Murthy, Marie-Pierre Preziosi, Srinath Reddy, Mirta Roses Periago, Vasee Sathiyamoorthy, John-Arne Røttingen, Soumya Swaminathan, as the members of the Writing Committee, assume responsibility for the content and integrity of this article
medRxiv 2020.10.15.20209817; doi: https://doi.org/10.1101/2020.10.15.20209817

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9767)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1558)
  • Health Policy (735)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11641)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1176)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4655)
  • Radiology and Imaging (777)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)